- Home
- HXHX vs CNSP Comparison
HXHX vs CNSP Comparison
Compare HXHX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | CNSP |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | China | United States |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HXHX | CNSP |
|---|---|---|
| Price | $0.51 | $5.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.3M | 13.2K |
| Earning Date | 05-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.80 |
| 52 Week High | $1.84 | $10.59 |
Technical Indicators
Market Signals| Indicator | HXHX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 61.34 |
| Support Level | $0.51 | $5.15 |
| Resistance Level | $0.56 | $5.61 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 73.04 | 95.48 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.